Efficacy and Tolerability of Sensoril® in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections
NCT ID: NCT04733924
Last Updated: 2021-10-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
77 participants
INTERVENTIONAL
2021-01-21
2021-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Withania somnifera 125 mg
One capsule before breakfast for 84 days
Aqueous extract of roots plus leaves of Withania somnifera 125 mg
One capsule before breakfast for 84 days
Withania somnifera 250 mg
One capsule before breakfast for 84 days
Aqueous extract of roots plus leaves of Withania somnifera 250 mg
One capsule before breakfast for 84 days
Microcrystalline Cellulose
One capsule before breakfast for 84 days
Microcrystalline Cellulose
One capsule before breakfast for 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aqueous extract of roots plus leaves of Withania somnifera 125 mg
One capsule before breakfast for 84 days
Aqueous extract of roots plus leaves of Withania somnifera 250 mg
One capsule before breakfast for 84 days
Microcrystalline Cellulose
One capsule before breakfast for 84 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. High susceptibility to URTIs, defined as ≥ 4 URTI episodes within 12 months.
3. Presence of an active URTI episode (Defined as a score of ≥5 for atleast 2 of following 6 symptoms: runny nose, plugged nose, sneezing, sore throat, scratchy throat, or cough on the WURSS-21 assessment), with onset of symptoms within 48 hours prior to screening.
4. SpO2 ≥ 96% as assessed by fingertip pulse oximetry
5. Commitment to adhere to former diet and physical activities throughout the study period. 6. Able to comply and perform the procedures requested by the protocol (consumption of study medications, filling daily eDiary for health updates, biological sample collection procedures and study visit schedule) 7. Participants who are literate enough to understand the essence of study, are informed about the purpose of the study, and understand their rights. 8. Participants who are able to give written informed consent and are willing to participate in the study.
Exclusion Criteria
2. Clinical signs or Symptoms indicating lower respiratory tract infection.
3. Known sensitivity to the investigational product or any excipients of the drug product.
4. Any clinically significant abnormalities of the upper respiratory tract (such as stridor, laryngomalacia, etc.)
5. Any clinically significant acute or chronic respiratory illness (such as Sinusitis, pharyngitis/tonsillitis, etc.)
6. Chronic cough of any origin not accompanied to other symptoms of URTI
7. Unable to abstain from any home-based remedies for common cold such as steam inhalation, decoctions, vapour rub, etc. throughout the study period.
8. Presence of uncontrolled type 2 diabetes (Indicated by fasting blood glucose (FBG) ≥126 mg/dL)
9. Presence of uncontrolled hypertension (Defined as Systolic Blood Pressure (SBP) ≥ 140 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 90 mm Hg).
10. Participants with abnormal liver and kidney function tests, defined as:
* Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) levels \> 1.5 × upper level of normal
* Serum alkaline phosphatase (ALP) levels \> 1.5 × upper level of normal
* Serum creatinine levels \> 1.5 × upper level of normal
11. Unable to abstain from ginger, avocado, soy or other known dietary supplements for common cold throughout the study period.
12. Vaccination against influenza or swine flu within 3 months prior to screening.
13. Those who have taken or will be taking or are taking antibiotics, antivirals, steroids, nasal decongestants, antihistamines, or other medications that are expected to alleviate cold symptoms within two weeks prior to randomization.
14. History of any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points.
15. Individuals having a history (in past 2 years) of smoking or currently smoking or using any form of smokeless tobacco.
16. Participation in other clinical trials in last 90 days prior to screening
17. Participants with heavy alcohol consumption, defined as
* For men: More than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a day.
* For women: More than 7 SAD/week or more than 3 SAD in a day. (NOTE - A standard alcoholic drink contains approximately 14 grams of alcohol, which is equivalent to 12 ounces of beer (\~5% alcohol), 8.5 ounces of malt liquor (\~9% alcohol), 5 ounces of wine (\~12% alcohol), 3.5 ounces of fortified wine (e.g., sherry or port), or 1.5 ounces of liquor (distilled spirits; \~40% alcohol).
18. Binge drinkers, defined as 4 or more SAD for women, and 5 or more SAD for men, in a 2-hour time frame.
19. History or presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
20. Participants who have clinically significant following severe illness (i.e., Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory, blood and tumors, gastrointestinal diseases, etc.)
21. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
22. Any condition that could, in the opinion of the investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vedic Lifesciences Pvt. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Rajesh Kewalramani Clinic
Mumbai, Maharashtra, India
Sanjivani Day Care and Ayurved Center,
Pālghar, Maharashtra, India
Care N Cure Multispeciality Hospital
Thāne, Maharashtra, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NT/200803/SENSORIL/URT
Identifier Type: -
Identifier Source: org_study_id